Valuation : Lexeo Therapeutics, Inc.

Market Cap 391M 336M 316M 288M 538M 37.02B 541M 3.74B 1.45B 18.92B 1.47B 1.43B 60.22B P/E 2026 *
-3.91x
P/E 2027 * -3.46x
Enterprise Value 213M 183M 172M 157M 293M 20.18B 295M 2.04B 789M 10.31B 799M 782M 32.82B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Lexeo Therapeutics, Inc.

1 day-2.66%
1 week+1.28%
1 month-1.04%
3 months+13.06%
6 months-30.51%
Current year-52.06%
1 week 4.66
Extreme 4.66
4.99
1 month 4.54
Extreme 4.54
5.4
Current year 3.99
Extreme 3.99
10.75
1 year 3.99
Extreme 3.99
10.99
3 years 1.45
Extreme 1.45
22.33
5 years 1.45
Extreme 1.45
22.33
10 years 1.45
Extreme 1.45
22.33
Manager TitleAgeSince
Chief Executive Officer 46 01/01/2020
Director of Finance/CFO 50 15/08/2025
Chief Tech/Sci/R&D Officer 62 20/01/2026
Director TitleAgeSince
Director/Board Member 46 01/01/2020
Chairman 72 01/01/2021
Director/Board Member 61 01/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
18/8/26 Sell

Chief Executive Officer

-3,345 0.0043%
18/8/26 Sell

Chief Operating Officer

-1,304 0.0017%
18/8/26 Sell

Chief Financial Officer

-4,117 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-2.66%+1.28%-9.33% - 401M
+2.02%+1.26%+41.37%+105.18% 67.82B
-0.41%-2.30%+33.53%+78.63% 63.22B
-1.11%+2.78%-14.86%+375.59% 27.58B
-4.92%-3.22%-3.90%-17.87% 26.06B
+0.77%+0.89%+31.92%+16.35% 25.38B
+1.12%+0.84%+24.50%-17.84% 19.89B
+6.04%+7.25%+233.25%+383.12% 17.4B
0.00%-1.30%-7.05%+523.05% 14.95B
-2.27%+1.37%+53.01%+160.83% 14.62B
Average -0.17%+1.15%+38.24%+178.56% 27.73B
Weighted average by Cap. +0.22%+0.44%+37.63%+140.46%

Financials

2026 *2027 *
Net sales - -
Net income -104M -89.19M -83.91M -76.58M -143M -9.83B -144M -994M -385M -5.03B -390M -381M -16B -130M -112M -105M -95.98M -179M -12.33B -180M -1.25B -482M -6.3B -488M -478M -20.05B
Net Debt -178M -153M -144M -131M -245M -16.85B -246M -1.7B -659M -8.61B -667M -653M -27.4B -305M -262M -247M -225M -421M -28.94B -423M -2.93B -1.13B -14.79B -1.15B -1.12B -47.08B
Logo Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Employees
63
Date Price Change Volume
08/09/26 USD 4.760 -2.66% 357,807
04/09/26 USD 4.890 +1.03% 296,442
03/09/26 USD 4.840 +1.26% 313,344
02/09/26 USD 4.780 +1.70% 468,357
01/09/26 USD 4.700 -1.26% 420,477
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.760USD
Average target price
20.30USD
Spread / Average Target
+326.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXEO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!